ArticleInternational urogynecology journal2026
The Impact of Treatment Setting on Periurethral Bulking.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydrogel-Based Therapies for Female Stress Urinary Incontinence: From Bulking Agents to Regenerative Platforms-A Narrative Review.Current urology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introduction and hypothesisWhether treatment setting impacts periurethral bulking efficacy is unknown. We hypothesized that periurethral bulking treatment failure rates would be greater for office versus operating room procedures.
methodsA retrospective cohort study including 113 patients undergoing polyacrylamide hydrogel periurethral bulking at a single academic medical center between 1 September 2022 and 30 March 2024 was carried out. Demographic and clinical variables, procedural details, patient satisfaction, and retreatment rates were abstracted. Primary outcomes included 6-month treatment failure, defined as no improvement following treatment, decision for additional therapy, or aborted procedure. Secondary outcomes included 12-month treatment failure and 6- and 12-month retreatment rates. Chi-squared, Fisher's exact, Mann-Whitney U, and t tests were applied, and logistic regression was used to identify factors associated with treatment failure.
resultsThe 6- and 12-month treatment failure rates in the operating room versus office cohorts were 32.4% vs 51.3% (p = 0.05) and 48.1% vs 50.0% (p = 0.87) respectively. Retreatment rates and modality did not differ. Approximately 15% of office cases but no operating room cases were unable to be completed as planned (p < 0.01). Office setting was associated with 3.23 increased odds of 6-month treatment failure (p < 0.05).
conclusionsPeriurethral bulking in the office may be more likely to result in early treatment failure than bulking performed in the operating room, but any benefit appears short lived, with similar 12-month treatment failure and retreatment rates. Our findings, together with consideration of individual patient characteristics and resource optimization, can guide decisions regarding the appropriate treatment setting for periurethral bulking.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.